Chemistry:Dalosirvat
Dalosirvat (INN, USAN; developmental code name SM-04554) is a drug acting as a Wnt signaling pathway stimulant which is under development for the treatment of alopecia (hair loss).[1][2][3][4] It is used topically as a solution.[1][3] The drug is being developed by Biosplice Therapeutics (formerly known as Samumed).[1][2] As of April 2021, it is in phase 2/3 clinical trials for this in Turkey.[1][2] There have been no further updates on the development of dalosirvat as of October 2025.[1] Two phase 2 trials have been completed and preliminary results released.[3] In one of the trials, only a 0.15% concentration and not a higher 0.25% concentration showed effectiveness.[3] A 625-patient phase 3 trial was reportedly started in 2018.[3] It was reported in a 2023 literature review that dalosirvat had completed a phase 3 trial in early 2023 and that Biosplice Therapeutics had cancelled its development based on the trial's results.[5]
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Biosplice Therapeutics". 19 April 2021. https://adisinsight.springer.com/drugs/800038979.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on SM-04554 with Synapse". 18 October 2025. https://synapse.patsnap.com/drug/928ac4439bf347b6934a6ac1f965775c.
- ↑ 3.0 3.1 3.2 3.3 3.4 "New drugs under investigation for the treatment of alopecias". Expert Opinion on Investigational Drugs 28 (3): 275–284. March 2019. doi:10.1080/13543784.2019.1568989. PMID 30642204.
- ↑ "Recent updates on Wnt signaling modulators: a patent review (2014-2020)". Expert Opinion on Therapeutic Patents 31 (11): 1009–1043. November 2021. doi:10.1080/13543776.2021.1940138. PMID 34128760.
- ↑ "The booming business of hair loss". Trends in Biotechnology 41 (6): 731–735. June 2023. doi:10.1016/j.tibtech.2022.12.020. PMID 36669948. "Embryonic conserved signaling pathways that have been consistently associated with hair cycle regulation and trichogenicity are Wingless (Wnt), Sonic hedgehog (Shh), Hairy and enhancer of split 1 (Hes1), fibroblast growth factor 7 (FG7), and keratinocyte growth factor (KGF). The Wnt/β-catenin signaling pathway has a key role in hair morphogenesis and cycling during both the embryonic stage and adult life. Therefore, pharmacological activation of the Wnt/β-catenin signaling has been explored for a long time to promote hair regeneration. Samumed (now Biosplice) was the first company to develop a topical solution for Wnt signaling activation in the balding scalp. Biosplice managed to value $12 billion in 2018, but earlier this year, upon conclusion of a phase 3 clinical trial, Biosplice canceled dalosirvat from clinical development.".
External links
 |  |
